KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: A practical approach

Polish Journal of Pathology

Volumn 63, Issue 3, 2012, Pages 145-164

  Domagała, Paweł ^a   Hybiak, Jolanta ^a   Sulzyc Bielicka, Violetta ^a   Cybulski, Cezary ^a   Ryś, Janusz ^b   Domagała, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Colorectal cancer; EGFR; KRAS; Molecular pathology; Targeted therapy

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

COLORECTAL TUMOR; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; PERSONALIZED MEDICINE; REVIEW;

COLORECTAL NEOPLASMS; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84869816018     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2012.31499     Document Type: Review

References (140)

1. Domagala P, Huzarski T, Lubinski J, et al. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011; 458: 55-64.
2. Bando I, Cillero L, Sanz-Ortega J, et al. Study of KRAS new predictive marker in a clinical laboratory. Clin Transl Oncol 2012 [Epub ahead of print].
3. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010; 17: 23-32.
4. Bedeir A, Krasinskas AM. Molecular diagnostics of colorectal cancer. Arch Pathol Lab Med 2011; 135: 578-587.
5. Malapelle U, Bellevicine C, SalatielloM, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. J Clin Pathol 2012; 65: 940-944.
6. Tai CJ, Chang CC, Jiang MC, et al. Clinical-pathological correlation of K-Rasmutation and ERK phosphorylation in colorectal cancer. Pol J Pathol 2012; 63: 93-100.
7. Wójcik P, Kulig J, Okoń K, et al. KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS. Pol J Pathol 2008; 59: 93-96.
8. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-862.
9. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-950.
10. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-4065.
11. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat 2005; 8: 369-380.
12. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
13. NormannoN, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
14. Grossmann AH, SamowitzWS. Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. Arch Pathol Lab Med 2011; 135: 1278-1282.
15. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
16. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
17. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRASmutation detection inmetastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
18. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
19. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
21. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
22. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractorymetastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
23. Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases 2012; 3: 34-39.
24. College of American Pathologists. POET Report: perspectives on emerging technology: KRAS testing for colorectal cancer. http://www.cap.org/apps/docs/committees/technology/KRAS.pdf. Published September 2009. Accessed August 22, 2012.
25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer V3.2012. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed August 22, 2012.
26. Dotti I, Bonin S, Basili G, Faoro V. Formalin-Free Fixatives. In: Guidelines for Molecular Analysis in Archive Tissues. Stanta G (ed.). Springer-Verlag, Berlin Heidelberg 2011; 13-18.
27. Nietner T, Jarutat T, Mertens A. Systematic comparison of tissue fixation with alternative fixatives to conventional tissue fixation with buffered formalin in a xenograft-based model. Virchows Arch 2012; 461: 259-269.
28. Baas JM, Krens LL, Guchelaar HJ, et al. Concordance of predictivemarkers for EGFR inhibitors in primary tumors andmetastases in colorectal cancer: a review. Oncologist 2011; 16: 1239-1249.
29. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219.
30. Boissière-Michot F, Lopez-Crapez E, FrugierH, et al. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Mod Pathol 2012; 25: 731-739.
31. Ross JS. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Arch Pathol Lab Med 2012; 136: 1298-1307.
32. Hunt JL, Finkelstein SD. Microdissection techniques formolecular testing in surgical pathology. Arch Pathol LabMed 2004; 128: 1372-1378.
33. Ogino S, Kawasaki T, BrahmandamM, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. JMol Diagn 2005; 7: 413-421.
34. Warth A, Penzel R, Brandt R, et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 2012; 460: 407-414.
35. Jimeno A, MessersmithWA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27: 1130-1136.
36. Aubin F, Gill S, Burkes R, et al. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr Oncol 2011; 18: e180-184.
37. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-4914.
38. Bando H, Yoshino T, Tsuchihara K, et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011; 105: 403-406.
39. Malapelle U, Carlomagno C, Salatiello M, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012; 107: 626-631.
40. Kimura T, Okamoto K, Miyamoto H, et al. Clinical benefit of high-sensitivity KRASmutation testing inmetastatic colorectal cancer treated with anti-EGFR antibody therapy. Oncology 2012; 82: 298-304.
41. Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009; 11: 1084-1092.
42. GiarettiW, Rapallo A, Sciutto A, et al. Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 2000; 21: 49-57.
43. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004; 325: 784-791.
44. Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26: 916-922.
45. Oltedal S, Aasprong OG, Møller JH, et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis 2011; 26: 1271-1277.
46. van Krieken JH, Jung A, Kirchner T, et al. KRASmutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453: 417-431.
47. Dequeker E, LigtenbergMJ, Vander Borght S, van Krieken JH. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Arch 2011; 459: 155-160.
48. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports inmolecular pathology. Arch Pathol LabMed 2007; 131: 852-863.
49. ScheunerMT, Hilborne L, Brown J, et al. A report template for molecular genetic tests designed to improve communication between the clinician and laboratory. Genet Test Mol Biomarkers 2012; 16: 761-769.
50. ISO 15189:2011. Medical laboratories-Particular requirements for quality and competence. Geneva: International Organization for Standardization.
51. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009; 16: 196-203.
52. College of American Pathologists. Labolatory general checklist. http://www.cap.org/apps/docs/laboratory_accreditation/checklists/ laboratory_general_sep07.pdf. Published September 27, 2009. Accessed August 22, 2012.
53. European Molecular Genetics Quality Network. Final Report 2011 (Round 2) Pilot EQA scheme for EGFR mutation testing in non-small cell lung cancer. Published May 17, 2012.
54. Organisation for Economic Co-operation and Development. OECD guidelines for quality assurance in molecular genetic testing. http://www.oecd.org/science/biotechnologypolicies/ 38839788.pdf. Published 2007. Accessed August 22, 2012.
55. Kamel-Reid S, Zhang T, Persons DL, et al. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol LabMed 2012; 136: 26-32.
56. Ciardiello F, Tejpar S, NormannoN, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011; 6: 133-145.
57. Bibeau F, Louvet C, Afchain P, et al. Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment. Bull Cancer 2012; 99: 743-751.
58. van Krieken JH, Hoefler G. The times have changed: molecular pathology is here to stay. A commentary on: analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Lee et al. In this issue. Virchows Arch 2012; 460: 129-130.
59. Moch H, Blank PR, Dietel M, et al. Personalized cancer medicine and the future of pathology. Virchows Arch 2012; 460: 3-8.
60. DietelM, Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 2006; 448: 744-755.
61. Angulo B, García-García E, Martínez R, et al. A commercial realtime PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010; 12: 292-299.
62. Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One 2011; 6: e29146.
63. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011; 16: 467-478.
64. Thunnissen E, Bovée JV, Bruinsma H, et al. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol 2011; 64: 884-892.
65. Kotoula V, Charalambous E, Biesmans B, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009; 4: e7746.
66. Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007; 13: 5115-5123.
67. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012; 25: 548-555.
68. Kristiansen G. Manualmicrodissection. MethodsMol Biol 2010; 576: 31-38.
69. Burgemeister R. Nucleic acids extraction fromlasermicrodissected FFPE tissue sections. Methods Mol Biol 2011; 724: 117-129.
70. Burton MP, Schneider BG, Brown R, et al. Comparison of histologic stains for use in PCR analysis of microdissected, paraffin-embedded tissues. Biotechniques 1998; 24: 86-92.
71. Murase T, Inagaki H, Eimoto T. Influence of histochemical and immunohistochemical stains on polymerase chain reaction. Mod Pathol 2000; 13: 147-151.
72. Morikawa T, Shima K, Kuchiba A, et al. No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from h&e-stained archival tissue sections. Am J Clin Pathol 2012; 138: 122-129.
73. Ludyga N, Grünwald B, Azimzadeh O, et al. Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses. Virchows Arch 2012; 460: 131-140.
74. Mittempergher L, de Ronde JJ, Nieuwland M, et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 2011; 6: e17163.
75. Yost SE, Smith EN, Schwab RB, et al. Identification of highconfidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res 2012; 40: e107.
76. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007; 7: 36.
77. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroformextraction. Anal Biochem 1987; 162: 156-159.
78. Okello JB, Zurek J, Devault AM, et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem 2010; 400: 110-117.
79. Turashvili G, YangW, McKinney S, et al. Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing andDNA/RNA extraction techniques. ExpMol Pathol 2012; 92: 33-43.
80. Muñoz-Cadavid C, Rudd S, Zaki SR, et al. Improving molecular detection of fungalDNA in formalin-fixed paraffin-embedded tissues: comparison of five tissue DNA extraction methods using panfungal PCR. J Clin Microbiol 2010; 48: 2147-2153.
81. Bonin S, Hlubek F, Benhattar J, et al. Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch 2010; 457: 309-317.
82. Bonin S, Groenen P, Halbwedl I, Popper HH. DNA Extraction from Formalin-Fixed Paraffin-Embedded (FFPE) Tissues. In: Guidelines for Molecular Analysis in Archive Tissues. Stanta G (ed.). Springer-Verlag, Berlin Heidelberg 2011; 33-36.
83. Hlubek F, Jung A. Fast Protocol for DNA Extraction from Formalin-Fixed Paraffin-Embedded Tissues. In: Guidelines forMolecular Analysis in Archive Tissues. Stanta G (ed.). Springer-Verlag, Berlin Heidelberg 2011; 41-43.
84. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem 1997; 249: 228-238.
85. Boesenberg-Smith K, Pessarakli M, Wolk D. Assessment of DNA Yield and Purity: an Overlooked Detail of PCR Troubleshooting. Clin Microbiol Newsl 2012; 34: 1-6.
86. Gallagher SR. Quantitation of DNA and RNA with absorption and fluorescence spectroscopy. Curr ProtocMol Biol 2011; Appendix 3: 3D.
87. Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011; 11: 635-642.
88. PaoW, LadanyiM. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007; 13: 4954-4955.
89. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-994.
90. Hoorens A, Jouret-Mourin A, Sempoux C, et al. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. Acta Gastroenterol Belg 2010; 73: 497-503.
91. TurnerNC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13: e178-185.
92. FranklinWA, Haney J, Sugita M, et al. KRAS mutation: comparison of testingmethods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43-50.
93. Pinto P, Rocha P, Veiga I, et al. Comparison of methodologies for KRASmutation detection inmetastatic colorectal cancer. Cancer Genet 2011; 204: 439-446.
94. Bando H, Tsuchihara K, Yoshino T, et al. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. Jpn J Clin Oncol 2011; 41: 239-244.
95. Kwon MJ, Lee SE, Kang SY, Choi YL. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011; 207: 762-768.
96. Kobunai T, Watanabe T, Yamamoto Y, Eshima K. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 2010; 395: 158-162.
97. Beau-Faller M, Legrain M, Voegeli AC, et al. Detection of KRas mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 2009; 100: 985-992.
98. Jeong D, Jeong Y, Lee J, et al. Rapid and sensitive detection of KRAS mutation by peptide nucleic acid-based real-time PCR clamping: a comparison with direct sequencing between fresh tissue and formalin-fixed and paraffin embedded tissue of colorectal cancer. Korean J Pathol 2011; 45: 151-159.
99. Hancer VS, Buyukdogan M, Türkmen I, et al. Comparison of KRAS mutation tests in colorectal cancer patients. Genet Test Mol Biomarkers 2011; 15: 831-834.
100. Marzinotto S, Sessa F, Franzoni A, et al. KRAS codons 12 and 13 mutation analysis: a comparative study between direct sequencing and a new sensitive real-time PCR assay. Sequencing 2011; Article ID 895709.
101. Lyon E, Wittwer CT. LightCycler technology in molecular diagnostics. J Mol Diagn 2009; 11: 93-101.
102. Palmirotta R, Ludovici G, De Marchis ML, et al. A comprehensive procedural approach to genotyping KRAS and BRAF fromparaffin embedded tissues for diagnostic purposes. In Vivo 2012; 26: 537-547.
103. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
104. Tol J, KoopmanM, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
105. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
106. Van CutsemE, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
107. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl JMed 2009; 361: 947-957.
108. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: 907-922.
109. Castle G, Blaney R. European Union Regulation of In Vitro Diagnostic Medical Devices. In: In Vitro Diagnostics: The Complete Regulatory Guide. Danzis SD, Flannery EJ (eds.). Food and Drug Law Institute, Washington D.C. 2010; 227-252.
110. Lee S, Brophy VH, Cao J, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch 2012; 460: 141-149.
111. European Society of Pathology. General report. ESP KRAS external quality assessment scheme 2011. http://kras. eqascheme.org. Published March 9, 2012.
112. Carotenuto P, Roma C, Rachiglio AM, et al. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010; 11: 1169-1179.
113. Ogasawara N, Bando H, Kawamoto Y, et al. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalinfixed, paraffin-embedded samples of colorectal cancers. Jpn J Clin Oncol 2011; 41: 52-56.
114. Nordgård O, Oltedal S, Janssen EA, et al. Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. DiagnMol Pathol 2012; 21: 9-13.
115. Ray A, Nordén B. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J 2000; 14: 1041-1060.
116. Thiede C, Bayerdörffer E, Blasczyk R, et al. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996; 24: 983-984.
117. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004; 111: 409-414.
118. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-7282.
119. Kriegshäuser G, Auner V, Schuster E, et al. KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reversehybridisation assay. J Clin Pathol 2011; 64: 252-256.
120. Ausch C, Buxhofer-Ausch V, Oberkanins C, et al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reversehybridization. J Mol Diagn 2009; 11: 508-513.
121. Gonzalez de Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalinfixed colorectal cancer specimens. Br J Cancer 2012; 107: 345-351.
122. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
123. Gaedcke J, Grade M, Jung K, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81.
124. Qiu P, Shandilya H, D'Alessio JM, et al. Mutation detection using Surveyor nuclease. Biotechniques 2004; 36: 702-707.
125. Jänne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12: 751-758.
126. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009; 11: 543-552.
127. Cavallini A, Valentini AM, Lippolis C, et al. KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res 2010; 30: 5251-5256.
128. Jennings L, Van Deerlin VM, GulleyML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 2009; 133: 743-755.
129. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010; 5: 23.
130. Tysarowski A, Fabisiewicz A, Kolasa I, et al. Validation of selected molecular methods for the mutations determination in codons 12 and 13 of K-RAS gene in five Polish oncological research centers. Onkol Prak Klin 2008; 4: 232-244.
131. Feigelson HS, Goddard KA, Johnson MA, et al. Reliability of KRAS mutation testing in metastaticcolorectal cancer patients across five laboratories. BMC Res Notes 2012; 5: 196.
132. European Society of Pathology. Who participated so far in the ESP KRAS EQA schemes with a genotyping score of ≥ 90%? http://kras.eqascheme.org/info/public/eqa/previous_ participants.xhtml. Published April 20, 2012. Accessed August 22, 2012.
133. Lassmann S, Werner M. Predictive pathology in routine diagnostics of solid tumors. Histol Histopathol 2012; 27: 289-296.
134. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16: 88-98.
135. Barabási AL, GulbahceN, Loscalzo J. Networkmedicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
136. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 3023-3028.
137. Stricker T, Catenacci DV, Seiwert TY. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 2011; 38: 173-185.
138. Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol 2012; 13: 233-234.
139. Getting personal. Nature 2011; 473: 253-254.
140. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-486.